US/UK/Canada

Share

Quotes

The acquisition of Cognita broadens Abilia’s portfolio in Norway and is in line with the strategy to build on Abilia’s strong position within assistive products and welfare technology
Anders Dahlgren, CEO
Pick a time period -
Tags ( Active)

Preliminary result for the fourth quarter

The fourth quarter did not close as strong as the previous year. The greatest deviation, compared to the fourth quarter of last year, relates to the significantly lower earnings in business area Specialty Pharma due to increased competition on the British market for Melatonin. Business areas Assistive Tech and Medtech had stable sales but lower margins than in the comparison quarter of last year, and thereby, do not compensate for the lower earnings in Specialty Pharma. Margin is impacted e.g. by product mix and inventory write-downs, affecting all business areas in the quarter. As a

Profit growth, stronger cash flow and acquisitions

THIRD QUARTER JULY-SEPTEMBER             · The Group’s net sales amounted to SEK 413.1 (364.5) million, an increase of 13 percent. · The Group’s EBITA was SEK 80.1 (66.4) million, an increase of 21 percent. Adjusted for items affecting comparability, the increase was 4 percent or 9 percent adjusted for move related costs. · The EBITA margin was 19.4 (18.2) percent. Adjusted for items affecting comparability, the margin was 16.7 percent. · Profit after tax amounted to SEK 53.3 (38.4) million. · Earnings per share amounted to SEK 3.6 (2.6). · Cash flow from operating

Continued strong growth – adjusted EBITA increased by 13 percent

SECOND QUARTER APRIL–JUNE                 The Group’s net sales amounted to SEK 457.7 (386.1) million, an increase of 19 percent. The Group’s EBITA was SEK 90.1 (72.2) million, an increase of 25 percent. Adjusted for items affecting comparability, the increase was 13 percent. The EBITA margin was 19.7 (18.7) percent. Adjusted for items affecting comparability, the margin was 17.8 percent. Profit after tax amounted to SEK 57.1 (46.8) million. Earnings per share amounted to SEK 3.8 (3.2). Cash flow from operating activities was SEK 70.9 (39.7) million. HALF-YEAR JANUARY–

Abilia acquires Picomed and Alert-IT

Abilia, a subsidiary to MedCap AB (publ) and part of Business Area Assistive Tech, has signed an agreement to acquire Picomed AS in Norway and ITS Designs Limited (Alert-IT) in the UK. The transaction is expected to close in the beginning of October. The acquired companies have a combined turnover of approx. 70 MNOK and 26 employees. The acquisition complements the offering of Abilia and the Business Area Assistive Tech in the areas of Environmental Control, Communication and Alarm. The purchase price consists of an initial cash payment of 51 MNOK at closing and an additional payment

Strong first quarter – EBITA up 46 percent

FIRST QUARTER, JANUARY-MARCH            · The Group’s net sales amounted to SEK 461.7 (380.2) million, an increase of 21 percent. · The Group’s EBITA was SEK 88.5 (45.3) million, an increase of 95 percent. Adjusted for items affecting comparability*), the increase was 46 percent. · The EBITA margin was 19.2 (11.9) percent. The EBITA margin adjusted for items affecting comparability*) in the comparative period was 16.0 percent. · Profit after tax amounted to SEK 56.0 (24.8) million. · Earnings per share amounted to SEK 3.8 (1.7). · Cash flow from operating activities was

Abilia acquires Kompany AS and the product Komp

Abilia, a subsidiary to MedCap AB (publ) and part of Business Area Assistive Tech, has signed an agreement to acquire the company Kompany AS in Norway. The acquisition broadens Abilia’s offering within welfare technology for communication and social interaction. Kompany AS, which is a carve-out from No Isolation AS, offers the product Komp to assist in social interaction and reduce elderly’s involuntary isolation. Sales amounted to approx. 20 mNOK in 2023. Abilia has today paid 20 mNOK at closing of the transaction. The acquisition is expected to have a marginally positive impact on

Continued strong growth in the quarter – EBITDA increased by 42 percent

FOURTH QUARTER OCTOBER-DECEMBER     · The Group’s net sales amounted to SEK 456.6 (322.8) million, an increase of 41 percent. · The Group’s EBITDA was SEK 104.5 (73.3) million, an increase of 42 percent. · The EBITDA margin was 23 (23) percent. · Profit after tax amounted to SEK 62.2 (40.5) million. · Earnings per share amounted to SEK 4.2 (2.7). · Cash flow from operating activities was SEK 74.7 (-39.1) million. TWELVE MONTHS JANUARY-DECEMBER · The Group’s net sales amounted to SEK 1,587.4 (1,111.3) million, an increase of 43 percent. · The Group’s EBITDA was

Continued strong growth in the quarter – EBITDA increased by 63 percent

THIRD QUARTER JULY-SEPTEMBER             ·The Group’s net sales amounted to SEK 364.5 (241.5) million, an increase of 51 percent. ·The Group’s EBITDA was SEK 81.0 (69.7) million, an increase of 16 percent. Adjusted for items affecting comparability previous year[*)], the increase was 63 percent. ·The EBITDA margin was 22 (29) percent. Adjusted for items affecting comparability[*)], the margin was 22 (21) percent. ·Profit after tax amounted to SEK 38.3 (36.6) million. ·Earnings per share amounted to SEK 2.6 (2.5). ·Cash flow from operating activities

MedCap acquires Swedelift

MedCap has through the subsidiary Trident Industri AB acquired Swedelift AB, that will become part of MedCap’s cluster of assistive technology businesses.Swedelift sells and installs lifts to enable accessibility in homes and public buildings. The company has grown into a leading provider of lifts in its segment in Sweden. Trident has since 1995 manufactured ramps and today has a broad offering for home adaptations and accessibility. The acquisition enables a stronger offering to a larger market. Swedelift’s sales in 2022 amounted to 96 mSEK and operating profit to 9.5 mSEK.

Continued strong growth – EBITDA increased by 46 percent

SECOND QUARTER APRIL–JUNE            · The Group’s net sales amounted to SEK 386.1 (284.1) million, an increase of 36 percent. · The Group’s EBITDA was SEK 86.6 (59.4) million, an increase of 46 percent. · The EBITDA margin was 22 (21) percent. · Profit after tax amounted to SEK 46.8 (21.1) million. · Earnings per share amounted to SEK 3.2 (1.4). · Cash flow from operating activities was SEK 39.7 (24.4) million. HALF-YEAR JANUARY–JUNE · The Group’s net sales amounted to SEK 766.3 (546.9) million, an increase of 40 percent. · The Group’s EBITDA was SEK 146.0 (

MedCap acquires SurgiCube and Toul Meditech

MedCap AB (publ) has signed an agreement to acquire the company SurgiCube International B.V. (“SurgiCube”). The acquisition includes both the SurgiCube business based in the Netherlands and the Toul Meditech business based in Sweden.The SurgiCube group’s products provide ultra clean air around the operating surface and is a high quality and cost-effective solution for both hospitals and smaller clinics. The solutions are used in both ophthalmic and orthopedic surgery; and are mainly sold throughout Europe. Over the past 10+ years the business has established a strong offering, with an

Strong growth in the first quarter – adjusted EBITDA up 33 percent

FIRST QUARTER, JANUARY-MARCH      · The Group’s net sales amounted to SEK 380.2 (262.8) million, an increase of 45 percent. · The Group’s EBITDA was SEK 59.4 (56.3) million, an increase of 6 percent. EBITDA adjusted for items affecting comparability[*) ]amounted to 74.8 million, an increase of 33 percent. · The EBITDA margin was 16 (21) percent (20 percent adjusted for items affecting comparability[*)]). · Profit after tax amounted to SEK 24.8 (19.7) million. · Earnings per share amounted to SEK 1.7 (1.3). · Cash flow from operating activities was SEK 52.5 (56.3) million.

Strong organic growth in both the quarter and the year

FOURTH QUARTER OCTOBER-DECEMBER                  · The Group’s net sales amounted to SEK 322.8 (257.9) million, an increase of 25 percent. · The Group’s EBITDA was SEK 73.3 (66.5) million, an increase of 10 percent. Adjusted for items affecting comparability[*)], the increase was 16 percent. · The EBITDA margin was 23 (26) percent. Adjusted for items affecting comparability[*)], the margin was 23 (24) percent. · Profit after tax amounted to SEK 40.5 (40.8) million. · Earnings per share amounted to SEK 2.7 (2.7). · Cash flow from operating activities was SEK -39.1 (42.6)

MedCap AB (publ) announces the final outcome in its recommended cash offer to the shareholders of AdderaCare

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SCHWEIZ, SOUTH AFRICA OR THE UNITED STATES (THE ”RESTRICTED JURISDICTIONS”), OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION

MedCap announces the final outcome in its recommended cash offer to the shareholders of AdderaCare

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SCHWEIZ, SOUTH AFRICA OR THE UNITED STATES (THE ”RESTRICTED JURISDICTIONS”), OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION

MedCap completes the recommended cash offer to the shareholders of AdderaCare and extends the acceptance period

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA OR THE UNITED STATES (THE ”RESTRICTED JURISDICTIONS”), OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE

Offer document regarding the offer to the shareholders of AdderaCare made public

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA OR THE UNITED STATES (THE ”RESTRICTED JURISDICTIONS”), OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE

MedCap AB (publ) announces a recommended cash offer at a price of SEK 3.60 per share to the shareholders of AdderaCare AB (publ)

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SCHWEIZ, SOUTH AFRICA OR THE UNITED STATES (THE ”RESTRICTED JURISDICTIONS”), OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION

Sales and earnings growth – EBITDA increased by 32%

THIRD QUARTER JULY-SEPTEMBER         · The Group’s net sales amounted to SEK 241.5 (202.3) million, an increase of 19 percent. · The Group’s EBITDA was SEK 69.7 (49.5) million, an increase of 41 percent. The increase was 32 (24) percent adjusted for non-recurring items. · The EBITDA margin was 29 (24) percent. Adjusted for non-recurring items, the margin was 21 (19) percent. · Profit after tax amounted to SEK 36.6 (25.7) million. · Earnings per share amounted to SEK 2.5 (1.8). · Cash flow from operating activities was SEK 43.8 (23.2) million. NINE MONTHS JANUARY-

A strong quarter throughout the Group - EBITDA increased by 29 percent

SECOND QUARTER APRIL–JUNE · The Group’s net sales amounted to SEK 284.1 (233.4) million, an increase of 22 percent. · The Group’s EBITDA was SEK 59.4 (46.1) million, an increase of 29 percent. · The EBITDA margin was 21 (20) percent. · Profit after tax amounted to SEK 21.1 (16.4) million. · Earnings per share amounted to SEK 1.4 (1.1). · Cash flow from operating activities was SEK 24.4 (33.1) million. HALF-YEAR JANUARY–JUNE · The Group’s net sales amounted to SEK 546.9 (456.0) million, an increase of 20 percent. · The Group’s EBITDA was SEK 115.6 (86.6)

MedCap divests Vitamin D

MedCap AB (publ) has, through its subsidiary Unimedic Pharma AB, signed an agreement to divest the rights to the product Vitamin D to Pharmaprim AB.The sales price and capital gain amount to 20 mSEK and generates a positive one-time effect in the third quarter. In 2021, the product’s sales amounted to 3.2 mSEK and the divestment is expected to have a marginal effect on MedCap’s sales and profitability. The sale supports the focus of the company’s specialty pharma portfolio.

Abilia acquires Cognita AS

MedCap (publ) has, through its subsidiary Abilia, signed an agreement to acquire the company Cognita AS (“Cognita”). The transaction has an important value to Abilia, that has a leading position in assistive technology in the Nordics, by strengthening and broadening the position within digital assistive products.Cognita has since many years established a strong position in assistive products in Norway. The company’s turnover in 2021 was 15 mNOK with good profitability. Abilia pays 12 mNOK in cash on closing, which is planned for June 1, 2022. The acquisition is expected to have a marginally

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe